citalopram for menopause
Systematic review and review evidence indicate citalopram reduces the frequency and severity of menopausal vasomotor symptoms by approximately 40-65%.
Hypothesized mechanism
Serotonergic modulation by SSRIs may stabilize central thermoregulatory pathways, reducing hot flash frequency and severity.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 8 of 10 overall, a strong reading, from a direct rated strong in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
Evidence comes from a systematic review (claim 1) and a review article (claim 2), but a single synthesis does not constitute independent replication. No large low-bias RCT or three+ independent consistent studies are presented, so this scores 1.
Rigor
Claim 1 is from a systematic review of SSRI/SNRIs for vasomotor symptoms, which qualifies as a high-rigor design (meta-analysis/systematic review tier). Claim 2 is a narrative review summarizing efficacy estimates.
Specificity
Both claims explicitly name citalopram and address menopausal vasomotor symptoms (hot flashes) in menopausal women. The drug and condition are directly identified.
Plausibility
SSRIs reducing vasomotor symptoms via serotonergic modulation of thermoregulation is mechanistically plausible, but the claims do not explicitly state or evidence a mechanism. The numeric reduction (40-65%) supports effect but not mechanism.
Consistency
Both sources agree in direction: citalopram reduces frequency and severity of hot flashes, with claim 2 quantifying a 40-65% reduction. The two independent reviews are directionally consistent.
Independent reading, reported beside the score
One outside model cross-reference is reported alongside the composite score. It is recorded separately and is not combined into the score.
MATRIX cross-reference Top 6%
Every Cure’smachine-learned treatment-probability model, drawn from a biomedical knowledge graph across roughly 1,800 drugs and 22,000 diseases. It provides a model-based estimate of how plausible a drug-disease link is given the structure of biomedical knowledge, reported alongside the substrate’s own evidence.
For this pair. MATRIX places this pair at Top 6%, with a treat-score of 3.41 (higher is better; across the pairs we cover, scores span about 3.1 to 4.5).
Scored over MATRIX’s own entities, confirming the same drug and disease: CHEBI:3723 (drug) and MONDO:0001119 (disease). Validate against the source: Every Cure’s MATRIX dataset ↗.
More on the MATRIX cross-reference and its provenance →Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Paroxetine, citalopram, and escitalopram appear to have the fewest adverse effects. PubMed · PMID 24944075 ↗
- 2paroxetine, citalopram, escitalopram, venlafaxine, and desvenlafaxine are effective in reducing the frequency and severity of hot flashes PubMed · PMID 24944075 ↗
- 3citalopram, desvenlafaxine, escitalopram, gabapentin, paroxetine, and venlafaxine are available and are associated with a reduction in frequency of vasomotor symptoms by approximately 40% to 65% PubMed · PMID 36749328 ↗
- 4In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 2393 report(s) of INSOMNIA were recorded for citalopram among female patients (of 84015 female reports for citalopram in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests citalopram acts on a system relevant to menopause — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →